Neuroimaging the Impact of Treatment on Neural Substrates of Trust in Post-Traumatic Stress Disorder (PTSD)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT01244477
First received: November 17, 2010
Last updated: August 22, 2014
Last verified: August 2014
  Purpose

Traumatic experiences can have a profound negative effect on the lives and well-being of both the people who experience them and their loved ones. For those who experience post-traumatic stress disorder (PTSD), their interpersonal difficulties and social support further impact the success of treatment such that interpersonal difficulties are associated with mistrust and predict poor treatment outcome. In this proposal, we use functional neuroimaging to understand the neurobiology of trust and mistrust in people with PTSD and to learn more about how successful treatment can improve trust and social functioning.


Condition Intervention
Stress Disorders, Post Traumatic
Trust
Behavioral: Group CPT-C

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Neuroimaging the Impact of Treatment on Neural Substrates of Trust in PTSD

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Continuous whole brain imaging with standard imaging parameters for each fMRI scan [ Time Frame: Pre & post a 12 week treatment group ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Behavioral Expression of trust on the trust game [ Time Frame: Pre & post a 12 week treatment group ] [ Designated as safety issue: No ]
  • The Clinician Administered PTSD Scale (CAPS) [ Time Frame: Pre & post a 12 week treatment group ] [ Designated as safety issue: No ]
  • PTSD Checklist (PCL) [ Time Frame: Administered each week at weekly group sessions ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: May 2011
Estimated Study Completion Date: August 2015
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Participants in group CPT-C
Behavioral: Group CPT-C
Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
No Intervention: Arm 2
Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).

Detailed Description:

Substantial recent data highlight the role of social functioning as a primary moderator of therapeutic response in individuals with post-traumatic stress disorder (PTSD) such that interpersonal difficulties and mistrust significantly and negatively impact treatment efficacy (Forbes et al., 2003; Forbes et al., 2005; Forbes et al., 2008). In addition, ample evidence suggests that psychotherapy improves the social and interpersonal lives of psychotherapy clients through improving clients' abilities to regulate their emotions and reduce social isolation (Yalom & Leszcz, 2005; Foy et al., 2000). While considerable research has been dedicated to exploring the neurobiology of emotional dysregulation associated with PTSD (Rauch, Shin, & Phelps, 2006; Etkin & Wager, 2007), and increasing data suggest that diverse psychotherapies affect neural functioning (Beauregard 2007), very little is understood about the neurobehavioral pathology underlying the debilitating interpersonal difficulties in PTSD, or the neurobiological mechanisms accompanying the improvements in social functioning that occur with efficacious therapy.

Thus, the broad goals of this project are two-fold. First, we seek to examine the neural substrates associated with interpersonal dysfunction in PTSD using a social exchange game previously developed to assess interpersonal trust and cooperation in healthy (King-Casas et al., 2005) and psychiatric groups (Chiu et al., 2008; King-Casas et al., 2008). Second, we seek to examine changes in neurobehavioral substrates of social functioning following treatment for veterans with PTSD. Specifically, we propose to use functional magnetic resonance imaging (fMRI) and behavior within a well-characterized Trust Game to examine the neural substrates associated with interpersonal trust and cooperation in veterans with PTSD prior to and following empirically supported psychotherapy cognitive processing therapy (CPT) for PTSD.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meet criteria for PTSD on the CAPS
  • Priority will be given to veterans aged 18-50 who have had an onset of symptoms in the past 10 years and are veterans of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF)
  • Have been referred for placement in CPT treatment by a clinician in the Trauma Recovery Program at the Michael E DeBakey VA Medical Center (MEDVAMC) or an eligible Veteran who contacts study staff.
  • Are able to see the computer display clearly with or without MR-compatible corrective lenses
  • Are free from current non-psychiatric medical problems impacting cognitive functioning.
  • Are cleared to participate by a treating MEDVAMC clinician
  • Are able to participate in fMRI

Exclusion Criteria:

  • Meet DSM-IV criteria for drug or alcohol abuse in the past 30 days
  • History of moderate to severe traumatic brain injury based on any of the following:

    • (i) Glasgow Coma Score < 13
    • (ii)alteration of consciousness > 24 hours; loss of consciousness,30 minutes
  • Presence of contraindications to MRI, including but not limited to:

    • claustrophobia
    • pacemaker
    • metal in eyes
    • other implants
  • Current neurological or general medical conditions known to impact cognitive and/or emotional functioning, including but limited to:

    • epilepsy
    • Parkinson's disease
    • Huntington's disease
    • Alzheimer's disease
    • stroke
    • chemotherapy for cancer
  • Acute psychological instability as assessed by a Michael E DeBakey VA Medical Center (MEDVAMC) clinician or study staff
  • Concurrent diagnosis of:

    • schizophrenia
    • schizoaffective disorder
    • delusional disorder
    • organic psychosis
    • and subjects taking antipsychotic medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01244477

Locations
United States, Texas
Michael E. DeBakey VA Medical Center (152)
Houston, Texas, United States, 77030
Sponsors and Collaborators
Investigators
Principal Investigator: Wright Williams, PhD Michael E. DeBakey VA Medical Center (152)
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT01244477     History of Changes
Other Study ID Numbers: B7760-P
Study First Received: November 17, 2010
Last Updated: August 22, 2014
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Stress Disorders, Post Traumatic
Trust
functional Magnetic Resonance Imaging (fMRI)

Additional relevant MeSH terms:
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 28, 2014